StockData
Bausch & Lomb Corp logo

Bausch & Lomb Corp (BLCO) company profile

BLCONYSEOphthalmic GoodsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 9/3029% below fair value
$20.83−0.05 (-0.24%)

Close on Nov 17, 2026Market cap $7.45BP/E –Yield –

About Bausch & Lomb

Ophthalmic Goods, SIC 3851

Bausch + Lomb Corporation develops, manufactures, and markets eye health products worldwide across three operating segments: Vision Care, Pharmaceuticals, and Surgical. Its Vision Care unit provides contact lenses, including daily disposables and specialty lenses, as well as consumer eye care items such as lens care solutions, over-the-counter eye drops, and nutritional supplements. The Pharmaceuticals division offers prescription and generic medications for ocular conditions, including dry eye disease, glaucoma, ocular hypertension, and post-operative inflammation. The Surgical segment supplies ophthalmic surgical devices, diagnostic and procedural equipment, intraocular lenses, delivery systems, and surgical instruments. The company provides its products to patients, consumers, eye care professionals, optometrists, physicians, and retail partners.

The company operates globally with approximately 13,000 employees and maintains a business presence across approximately 100 countries. Its research and development network comprises 13 facilities with around 900 dedicated personnel working on clinical programs worldwide. The provided text does not identify the location of its corporate headquarters.

Summary of the business section of Bausch & Lomb's latest annual report, written by StockData.

Company profile

Company

Legal name
Bausch & Lomb Corp
Founded
1853
Headquarters
Vaughan, A6
Address
520 Applewood Crescent L4K 4B4
Phone
(908) 541-5456
Website
bausch.com
Employees
13,000, Dec 31, 2025
Industry
Ophthalmic Goods
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, Florham Park, New Jersey

Stock & identifiers

Ticker
BLCO
Exchange
NYSE
IPO date
May 6, 2022
Shares outstanding
357M, Oct 21, 2026
Public float
$556.99M, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1860742
CUSIP
071705107
ISIN
US0717051074
FIGI
BBG014KG1L68
Share class FIGI
BBG014KG1GY8
LEI
549300NY6OZM39SO6475
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Brent L. SaundersChairman of the Board and CEO, Director974,158
Frederick MunschSVP, Controller and CAO45,831
Andrew J. StewartPresident, GPIC103,211
Luc BonnefoyPresident, Surgical103,801
A. Robert D. BaileyEVP & Chief Legal Officer264,241
Sam EldessoukyEVP and CFO393,527
Yehia HashadEVP of R&D and CMO187,350
Eduardo AlfonsoDirector32,197
John PaulsonDirector90,948
Russel C. RobertsonDirector95,516
Thomas AppioDirector27,583
Laurence E. PaulDirector11,776
Robert J. ChersiDirector11,776
Barbara TrebbiDirector11,776
Eschenbach Andrew C. VonDirector63,733
Thomas W. Ross Sr.Director85,233
Sarah B. KavanaghDirector69,541
Karen LingDirector61,518
Steven H. CollisDirector42,003
Nathalie D. BernierDirector85,505
Brett IcahnDirector61,147
Gaoxiang HuDirector61,147

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Brenton LSaunders
$32.19M$27.23M$3.47M$85$91
FY2025
Joseph CPapa
$0$0$3.47M$85$91
FY2024
Brenton LSaunders
$23.86M$21.41M$5.24M$90$94
FY2024
Joseph CPapa
$0$0$5.24M$90$94
FY2023
Brenton LSaunders
$45.31M$36.16M$4.32M$85$103
FY2023
Joseph CPapa
$9.53M$5.64M$4.32M$85$103

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
Brenton L. Saunders
Chairman of the Board and Chief Executive Officer
$1.60M–$23.78M$2.80M$4.00M$15.75K$32.19M+35%
Sam A. Eldessouky
Executive Vice President and Chief Financial Officer
$777.98K$250.00K$2.51M$660.00K$744.00K$15.75K$4.96M-27%
A. Robert D. Bailey
Executive Vice President and Chief Legal Officer
$767.94K–$1.71M$450.00K$673.20K$27.25K$3.63M-34%
Yehia Hashad, M.D.
Executive Vice President of Research & Development and Chief Medical Officer
$726.12K–$1.07M$280.00K$700.80K$15.75K$2.79M-38%
Andrew J. Stewart
President, Global Pharmaceuticals and International Consumer
$629.08K–$990.63K$260.00K$604.80K$15.75K$2.50M-39%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
May 6, 2022
Offer price
$18.00
Exchange
NYSE
First trading day
May 6, 2022
First-day close
$20.00+11.1%
Lock-up ends (est.)
Nov 2, 2022

“The initial public offering price is $18.00 per common share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had approximately 13,000 employees, which included approximately 7,000 in production, 4,200 in sales and marketing, 900 in general and administrative positions and 900 in R&D.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?